新型羊毛硫抗生素CMB001抗MRSA疗效研究
本研究评估新型羊毛硫抗生素CMB001对耐甲氧西林金黄色葡萄球菌(MRSA)的体外和体内疗效。CMB001在血液或血浆中24小时内保持抗菌活性,能破坏生物膜内细菌细胞壁。在小鼠中性粒细胞减少大腿感染模型中,CMB001降低细菌负荷的效果与万古霉素相当。
要点
- CMB001在血液或血浆中37°C下24小时维持抗菌活性。
- CMB001通过破坏细胞壁有效杀灭生物膜内金黄色葡萄球菌。
- 小鼠模型中CMB001降低MRSA负荷效果与万古霉素相当。
核心结论
- CMB001有望作为对抗MRSA的替代治疗选择。
研究设计与样本
- 体外评估CMB001在全血或贫血小板血浆中的抗菌活性及对金黄色葡萄球菌生物膜的杀菌效果。
- 测定小鼠最大耐受剂量并进行初步药代动力学分析。
- 采用中性粒细胞减少小鼠大腿感染模型评估体内疗效。
主要发现
- CMB001在血液或血浆存在下37°C维持抗菌活性长达24小时。
- CMB001通过显著破坏细菌细胞壁有效杀灭生物膜内金黄色葡萄球菌。
- 小鼠最大耐受剂量为10 mg/kg,经抗组胺药预处理后可提高至30 mg/kg。
- 在中性粒细胞减少MRSA感染小鼠中,CMB001降低细菌负荷的疗效与万古霉素相当。
临床怎么用
- CMB001可能作为MRSA感染的替代治疗选项,尤其针对生物膜相关感染。
局限性
- 结论基于小鼠模型,需进一步评估对其他病原体感染的体内疗效。
- 需扩展CMB001的药代动力学/药效学参数和安全性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy of a novel lantibiotic, CMB001, against MRSA biofilms in vitro and in an in vivo experimental model of bacterial infection. METHODS: Antibacterial activity of CMB001 was measured in vitro after its exposure to whole blood or to platelet-poor plasma. In vitro efficacy of CMB001 against a Staphylococcus aureus biofilm was studied using scanning electron microscopy. The maximum tolerable dose in mice was determined and a preliminary pharmacokinetic analysis for CMB001 was performed in mice. In vivo efficacy was evaluated in a neutropenic mouse thigh model of infection. RESULTS: CMB001 maintained its antibacterial activity in the presence of blood or plasma for up to 24 h at 37°C. CMB001 efficiently killed S. aureus within the biofilm by causing significant damage to the bacterial cell wall. The maximum tolerable dose in mice was established to be 10 mg/kg and could be increased to 30 mg/kg in mice pretreated with antihistamines. In neutropenic mice infected with MRSA, treatment with CMB001 reduced the bacterial burden with an efficacy equivalent to that of vancomycin. CONCLUSIONS: CMB001 offers potential as an alternative treatment option to combat MRSA. It will be of interest to evaluate the in vivo efficacy of CMB001 against infections caused by other pathogens, including Clostridioides difficile and Acinetobacter baumannii, and to expand its pharmacokinetic/pharmacodynamic parameters and safety profile.
引用
- Karczewski J, Brown CM, Maezato Y, et al. Efficacy of a novel lantibiotic, CMB001, against MRSA. J Antimicrob Chemother. 2021. PMID: 33582800. doi:10.1093/jac/dkab040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。